Relative Bioavailability Study of HRG2010 in Healthy Subjects
Status:
COMPLETED
Trial end date:
2021-10-07
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, open-label, four-period, crossover study. Primary Objective
1. To evaluate the pharmacokinetic characteristics of healthy subjects after a single oral dose of HRG2010 capsules at dose 1 and dose 2 under fasting conditions, and to compare these with the pharmacokinetic characteristics of Carbidopa/Levodopa Extended-Release Tablets (Sinemet) and Benserazide/Levodopa Tablets (Madopar).
Secondary Objective
2. To assess safety following administration.
Phase:
PHASE1
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
benserazide, levodopa drug combination carbidopa, levodopa drug combination